An overview of novel therapies for acute hereditary angioedema

American Journal of Clinical Dermatology

Volumn 11, Issue 6, 2010, Pages 383-388

  Firszt, Rafael ^a   Frank, Michael M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DRUG DERIVATIVE; ECALLANTIDE; HORMONE ANTAGONIST; ICATIBANT; KALLIKREIN; PEPTIDE; TRANEXAMIC ACID;

ACUTE DISEASE; ANGIONEUROTIC EDEMA; DRUG ANTAGONISM; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANDROGENS; ANTIFIBRINOLYTIC AGENTS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; DANAZOL; HEREDITARY ANGIOEDEMA TYPE III; HEREDITARY ANGIOEDEMA TYPES I AND II; HORMONE ANTAGONISTS; HUMANS; KALLIKREINS; PEPTIDES; RECEPTORS, BRADYKININ; TRANEXAMIC ACID;

EID: 79952109050     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11537030-000000000-00000     Document Type: Review

References (40)

1. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653-68
2. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-74 (Pubitemid 43255068)
3. Berinert® (C1 esterase inhibitor [human]): US prescribing information [online]. Available from URL: http://www.cslbehring-us.com/docs/892/886/ Berinert%20Nov%2009%20PI.pdf [Accessed 2010 Jul 28]
4. Frank MM. Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. Arthritis Rheum 1979; 22: 1295-9 (Pubitemid 10163796)
5. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-54 (Pubitemid 30187107)
6. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 589-93
7. Davis III AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006; 26: 633-51
8. Landerman NS, Webster ME, Becker EL, et al. Hereditary angioneurotic edema. J Allergy 1962; 33: 330-41
9. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963; 35: 37-44
10. Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148: 957-8
11. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006 Dec; 79 (6): 1098-104
12. Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med 2008; 359:1027-36
13. Markovic SN, Inwards DJ, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 2000; 133 (10): 839
14. Cacoub P, Fremeaux-Bacchi V, De Lacroix I, et al. A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum 2001; 44 (8): 1836-40 (Pubitemid 32758231)
15. Caldwell JR, Ruddy S, Schur PH, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopath 1972; 1: 39-52
16. Gelfand JA, Boss GR, Conley CL, et al. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) 1979; 58: 321-8 (Pubitemid 10194424)
17. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-8 (Pubitemid 8003704)
18. Rosse WF, Logue GL, Silberman HR, et al. The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levels. Trans Assoc Am Physicians 1976; 89: 122-32 (Pubitemid 8027918)
19. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181-7 (Pubitemid 11059821)
20. Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary antioneurotic edema). Ann Intern Med 1960; 53: 739-45
21. Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990; 54: 64-72 (Pubitemid 20197385)
22. Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005; 115: 864-9 (Pubitemid 40460866)
23. Schwartz RP. Ambiguous genitalia in a term infant due to exposure to danazol in utero [letter]. Am J Dis Child 1982; 136: 474 (Pubitemid 12156103)
24. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972; 286: 808-12
25. Cinryze™(C1 esterase inhibitor [human]): US prescribing information [online]. Available from URL: http://www.cinryze.com/documents/cinryze- prescribing-information.pdf [Accessed 2010 Jul 28]
26. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22
27. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8
28. Kalbitor® (ecallantide): US prescribing information [online]. Available from URL: http://www.kalbitor.com/pdf/ KalbitorFullPrescribingInformation.pdf [Accessed 2010 Jul 28]
29. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302: 542-6 (Pubitemid 10184278)
30. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-4 (Pubitemid 26192522)
31. Bork K. Hereditares angioneurtisches: Odem. Klinik sowie erweiterte diagnostiche und therapeutische Moglinkeiten. Dtsch Med Wochenschr 1979; 11: 405-9 (Pubitemid 9128009)
32. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema With C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161: 714-8 (Pubitemid 32200225)
33. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003; 29: 221-7 (Pubitemid 37315586)
34. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004; 114: 629-37 (Pubitemid 39194940)
35. Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-8
36. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11-7 (Pubitemid 44915550)
37. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47: 1028-32 (Pubitemid 46802091)
38. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 3: 255-8 (Pubitemid 37315589)
39. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-31
40. Cicardi M, Banerji M, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41